Trk Receptor
All Product Categories
-
Trk Receptor Inhibitors
(75)
View all products
-
Trk Receptor Agonists
(6)
View all products
-
Trk Receptor Antagonists
(3)
View all products
-
Trk Receptor Activators
(11)
View all products
-
Trk Receptor Modulators
(3)
View all products
-
Trk Receptor Degraders
(3)
View all products
-
Trk Receptor Control
(1)
View all products
-
Trk Receptor Related Products (116)
Related Products (116)
-
Entrectinib
0 ImagesSynonyms: NMS-E628; RXDX-101Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice.
-
Tanezumab
0 ImagesSynonyms: RN-624; PF 4383119Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia.
-
LM22A-4
0 ImagesLM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.
-
Bedinvetmab
0 ImagesSynonyms: ZTS-00508841Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs.
-
Gambogic amide
0 ImagesCat. No.: HY-121833CAS No.: 286935-60-2Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke.
-
BBT-176
0 ImagesBBT-176 is an orally active EGFR tyrosine kinase inhibitor. BBT-176 is a reversible ATP-competitive inhibitor with a unique binding mode, and it exhibits selectivity for mutant EGFR over wild-type EGFR. BBT-176 inhibits tumor growth, induces tumor regression, upregulates EGFR expression, and does not trigger secondary EGFR gene mutations. BBT-176 can be used in research related to non-small cell lung cancer.
-
JWJ-01-378
0 ImagesCat. No.: HY-175271JWJ-01-378 is a TPM3-TRKA fusion protein inhibitor and a wild-type TRK PROTAC degrader. JWJ-01-378 induces degradation via the ubiquitin-proteasome system, and does not degrade TRK inhibitor-resistant mutants or ALK fusion proteins. JWJ-01-378 inhibits downstream signaling pathways activated by TPM3-TRKA fusion, and reduces the viability of cancer cells harboring TPM3-TRKA fusion. JWJ-01-378 can be used to evaluate targeted degradation of TRK fusion proteins in cancer.
-
PD 90780
0 ImagesPD 90780 is a non peptide antagonist of nerve growth factor (NGF). PD 90780 interacts with NGF, prevents NGF binds with p75NTR. PD 90780 inhibits NGF-p75NTR interaction with IC50s of 23.1 and 1.8 μM in PC12 cells and PC12nnr5 cells, respectively .
-
Amdiglurax
0 ImagesSynonyms: NSI-189Amdiglurax (NSI-189) is an orally active chemical entity with enhanced neurogenic activity. Amdiglurax up-regulates neurogenic factors such as BDNF (brain derived-neurotrophic factor) and SCF. Amdiglurax exhibits anti-depressant effect. Amdiglurax enhances synaptic plasticity and reduces cognitive dysfunction. Amdiglurax holds potential for psychiatric disorder research.
-
Izenivetmab
0 ImagesCat. No.: HY-P99677CAS No.: 2447755-72-6Synonyms: ZTS-00075623Izenivetmab (ZTS-00075623) is an anti-NGFB IgG2κ monoclonal antibody. Izenivetmab shows anti-inflammatory and analgesic effects by targeting anti-nerve growth factor (NGF). Izenivetmab can be used for the research of osteoarthritis.
-
Fasinumab
0 ImagesSynonyms: REGN-475; SAR-164877Fasinumab (Anti-Human NGF) is a human IgG4 monoclonal antibody to nerve growth factor (NGF). Fasinumab can be used in acute sciatica and knee osteoarthritis (OA) studies.
-
DLK-IN-1
0 ImagesDLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research.
-
Ganglioside GM1 (bovine) ammonium
0 ImagesGanglioside GM1 (bovine) ammonium is a type of glycosphingolipid, mainly found on the cell membranes of the central nervous system of vertebrates. Ganglioside GM1 (bovine) ammonium exerts neuroprotective effects by reducing excessive activation of NMDAR, activating TrkA and ERK1/2, and inhibiting oxidative stress and cell apoptosis and autophagy. Ganglioside GM1 (bovine) ammonium can be used in the research of diseases such as traumatic brain injury, Parkinson's disease, Alzheimer's disease, and Huntington's disease.
-
Fulranumab
0 ImagesCat. No.: HY-P99200CAS No.: 902141-80-4
-
GNF-8625 monopyridin-N-piperazine hydrochloride
0 ImagesGNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1.
-
Frunevetmab
0 ImagesCat. No.: HY-P99627CAS No.: 1708936-80-4Synonyms: NV-02; PG110; ABT-110Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a Kd of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats.
-
Entrectinib-d8
0 ImagesSynonyms: NMS-E628-d8; RXDX-101-d8Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.
-
Utatrectinib
0 ImagesSynonyms: AZD-7451
